Your browser doesn't support javascript.
loading
Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients.
Mertens, Laura S; Claps, Francesco; Mayr, Roman; Bostrom, Peter J; Shariat, Shahrokh F; Zwarthoff, Ellen C; Boormans, Joost L; Abas, Cheno; van Leenders, Geert J L H; Götz, Stefanie; Hippe, Katrin; Bertz, Simone; Neuzillet, Yann; Sanders, Joyce; Broeks, Annegien; Peters, Dennis; van der Heijden, Michiel S; Jewett, Michael A S; Stöhr, Robert; Zlotta, Alexandre R; Eckstein, Markus; Soorojebally, Yanish; van der Schoot, Deric K E; Wullich, Bernd; Burger, Maximilian; Otto, Wolfgang; Radvanyi, François; Sirab, Nanour; Pouessel, Damien; van der Kwast, Theo H; Hartmann, Arndt; Lotan, Yair; Allory, Yves; Zuiverloon, Tahlita C M; van Rhijn, Bas W G.
Afiliação
  • Mertens LS; Dept. Urology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
  • Claps F; Dept. Urology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
  • Mayr R; Dept. Urology, Caritas St Josef Medical Center, University of Regensburg, Regensburg, Germany.
  • Bostrom PJ; Dept. Surgery (Urology) and Surgical Oncology, University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada; Dept. Urology, Turku University Hospital and University of Turku, Turku, Finland.
  • Shariat SF; Dept. Urology, University of Texas Southwestern Medical center, Dallas, TX.
  • Zwarthoff EC; Dept. of Pathology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands.
  • Boormans JL; Dept. Urology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands.
  • Abas C; Dept. of Pathology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands.
  • van Leenders GJLH; Dept. of Pathology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands.
  • Götz S; Dept. Urology, Caritas St Josef Medical Center, University of Regensburg, Regensburg, Germany.
  • Hippe K; Dept. Pathology, University Medical Center - Regensburg, Regensburg, Germany.
  • Bertz S; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen/Nurnberg, Erlangen, Germany.
  • Neuzillet Y; Dept. Urology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; Institut Curie, CNRS, UMR144, Molecular Oncology team, PSL Research University, Paris, France; Core Facility Molecular Pathology & Biobank, Netherlands Cancer Institute - Antoni van Leeuwen
  • Sanders J; Core Facility Molecular Pathology & Biobank, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
  • Broeks A; Core Facility Molecular Pathology & Biobank, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
  • Peters D; Core Facility Molecular Pathology & Biobank, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
  • van der Heijden MS; Dept. Medical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
  • Jewett MAS; Dept. Surgery (Urology) and Surgical Oncology, University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada.
  • Stöhr R; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen/Nurnberg, Erlangen, Germany.
  • Zlotta AR; Dept. Surgery (Urology) and Surgical Oncology, University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada.
  • Eckstein M; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen/Nurnberg, Erlangen, Germany.
  • Soorojebally Y; Institut Curie, CNRS, UMR144, Molecular Oncology team, PSL Research University, Paris, France.
  • van der Schoot DKE; Dept. Urology, Amphia Hospital, Breda, The Netherlands.
  • Wullich B; Dept. Urology & Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen/Nurnberg, Erlangen, Germany.
  • Burger M; Dept. Urology, Caritas St Josef Medical Center, University of Regensburg, Regensburg, Germany.
  • Otto W; Dept. Urology, Caritas St Josef Medical Center, University of Regensburg, Regensburg, Germany.
  • Radvanyi F; Institut Curie, CNRS, UMR144, Molecular Oncology team, PSL Research University, Paris, France.
  • Sirab N; Institut Curie, CNRS, UMR144, Molecular Oncology team, PSL Research University, Paris, France.
  • Pouessel D; Dept. Medical Oncology, Claudius Regaud Institute, Toulouse University Cancer Center (IUCT) Oncopole, Toulouse, France.
  • van der Kwast TH; Dept. Pathology, University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada.
  • Hartmann A; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen/Nurnberg, Erlangen, Germany.
  • Lotan Y; Dept. Urology, University of Texas Southwestern Medical center, Dallas, TX.
  • Allory Y; Institut Curie, CNRS, UMR144, Molecular Oncology team, PSL Research University, Paris, France; Dept. Pathology, Institut Curie, Paris, France.
  • Zuiverloon TCM; Dept. of Pathology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands; Dept. Urology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands. Electronic address: t.zuiverloon@erasmusmc.nl.
  • van Rhijn BWG; Dept. Urology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; Dept. Urology, Caritas St Josef Medical Center, University of Regensburg, Regensburg, Germany; Dept. Surgery (Urology) and Surgical Oncology, University Health Network, Princess Margaret Cancer
Urol Oncol ; 40(3): 110.e1-110.e9, 2022 03.
Article em En | MEDLINE | ID: mdl-34906411
OBJECTIVES: To determine the association between the FGFR3 mutation status and immuno-histochemistry (IHC) markers (p53 and Ki-67) in invasive bladder cancer (BC), and to analyze their prognostic value in a multicenter, multi-laboratory radical cystectomy (RC) cohort. PATIENTS AND METHODS: We included 1058 cN0M0, chemotherapy-naive BC patients who underwent RC with pelvic lymph-node dissection at 8 hospitals. The specimens were reviewed by uro-pathologists. Mutations in the FGFR3 gene were examined using PCR-SNaPshot; p53 and Ki-67 expression were determined by standard IHC. FGFR3 mutation status as well as p53 (cut-off>10%) and Ki-67 (cut-off>20%) expression were correlated to clinicopathological parameters and disease specific survival (DSS). RESULTS: pT-stage was
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Bexiga Urinária / Proteína Supressora de Tumor p53 Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male Idioma: En Revista: Urol Oncol Assunto da revista: NEOPLASIAS / UROLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Holanda
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Bexiga Urinária / Proteína Supressora de Tumor p53 Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male Idioma: En Revista: Urol Oncol Assunto da revista: NEOPLASIAS / UROLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Holanda